Terms: = Breast cancer AND MITF, WS2A, ENSG00000187098, 4286 AND Prognosis
4 results:
1. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham MP; Lucas P; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857525
[TBL] [Abstract] [Full Text] [Related]
2. Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers.
Osmanbeyoglu HU; Shimizu F; Rynne-Vidal A; Alonso-Curbelo D; Chen HA; Wen HY; Yeung TL; Jelinic P; Razavi P; Lowe SW; Mok SC; Chiosis G; Levine DA; Leslie CS
Nat Commun; 2019 Sep; 10(1):4369. PubMed ID: 31554806
[TBL] [Abstract] [Full Text] [Related]
3. Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer.
SebestyƩn E; Zawisza M; Eyras E
Nucleic Acids Res; 2015 Feb; 43(3):1345-56. PubMed ID: 25578962
[TBL] [Abstract] [Full Text] [Related]
4. mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-associated transcription factor-M, as a candidate biomarker for melanoma.
Wang Y; Radfar S; Liu S; Riker AI; Khong HT
BMC Med; 2010 Feb; 8():14. PubMed ID: 20163701
[TBL] [Abstract] [Full Text] [Related]